Ocular Therapeutix™ to Report First Quarter 2016 Financial Results
May 03 2016 - 04:05PM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report first quarter 2016 financial results
on Tuesday, May 10, 2016. Following distribution of the earnings
release via wire services, the Ocular Therapeutix management team
will host a live conference call and webcast at 8:00 a.m. Eastern
Time to review the Company's financial results and provide a
business update.
The live webcast can be accessed by visiting the Investors
section of the Company’s website at investors.ocutx.com. Please
connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to
access the webcast. Alternatively, please call 844-464-3934 (U.S.)
or 765-507-2620 (International) to listen to the conference call.
The conference ID number for the live call will be 3038508. An
archive of the webcast will be available until May 24, 2016 on the
Company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical
company focused on the development and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary hydrogel platform technology. Ocular Therapeutix's
lead product candidate, DEXTENZA™ (sustained release dexamethasone)
Intracanalicular Depot, is in Phase 3 clinical development for
post-surgical ocular inflammation and pain and allergic
conjunctivitis, and in Phase 2 clinical development for dry eye
disease. A New Drug Application (NDA) for the post-operative ocular
pain indication has been filed with FDA and has a Prescription Drug
User Fee Act (PDUFA) target action date of July 24, 2016. A third
Phase 3 clinical trial is being conducted for post-surgical ocular
inflammation and pain. For glaucoma and ocular hypertension, the
Company has completed its End-of-Phase 2 review with the FDA, and
the first of two planned OTX-TP Phase 3 clinical trials is expected
to be initiated in the third quarter of 2016. Ocular Therapeutix is
also evaluating sustained-release injectable anti-VEGF drug depots
for back-of-the-eye diseases. Ocular Therapeutix's first product,
ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160503006434/en/
InvestorsOcular Therapeutix, Inc.Brad SmithChief
Financial Officerbsmith@ocutx.comorBurns McClellan on behalf of
Ocular TherapeutixSteve Klass,
212-213-0006sklass@burnsmc.comorMediaOcular Therapeutix,
Inc.Scott CorningVice President of Sales and
Marketingscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2023 to Mar 2024